- Home
- VOR vs TVGN Comparison
VOR vs TVGN Comparison
Compare VOR & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VOR | TVGN |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.3M | 63.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VOR | TVGN |
|---|---|---|
| Price | $14.32 | $9.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 1 |
| Target Price | ★ $45.33 | N/A |
| AVG Volume (30 Days) | ★ 787.1K | 34.8K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.14 |
| 52 Week High | $49.95 | $12.00 |
Technical Indicators
Market Signals| Indicator | VOR | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 57.63 |
| Support Level | $13.73 | $0.44 |
| Resistance Level | $14.73 | $10.08 |
| Average True Range (ATR) | 0.85 | 1.59 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 52.53 | 57.46 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.